Kelunbotai’s PD-L1 monoclonal antibody “Tagolimab” has been approved for a new indication
January 22, 2025
Source: drugdu
30
On January 20, 2025, Kelunbotai's Tagolimab injection was approved by the State Food and Drug Administration again, with a new indication of first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin (acceptance number CXSS2400049). The approval of this new indication marks a further expansion of the application scope of Tagolimab in the treatment of nasopharyngeal carcinoma. Nasopharyngeal carcinoma is a malignant tumor that occurs in the nasopharynx. Because its location is hidden and its early symptoms are not obvious, it is often diagnosed in the middle and late stages.
https://bydrug.pharmcube.com/
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Six new drugs will be launched this year, aiming for 20 billion yuan January 22, 2025
- Two innovative medical devices enter the special review process January 22, 2025
- On the same day, the “twin giants” of insulin disclosed their performance forecasts, and Kangnuo and Nuocheng Jianhua jointly announced an authorized and licensed cooperation January 22, 2025
- Continuously optimistic about the innovative pharmaceutical industry January 22, 2025
- Huadong Medicine’s exclusive marketing product Cenaparib Capsules (Paisuning®) has been approved for marketing by NMPA January 22, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
